By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive and fast-moving environment, diversification is often framed as a necessary growth … Read more
Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial resistance potential. Dr. Watz in the accompanying press release: “The data … Read more
Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more
Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two decades of experience in clinical research operations, having held senior leadership … Read more
The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if it acts decisively. In his latest op-ed for BioSpace, Craig Koch examines why this moment matters for European clinical research. While the EEA’s share of … Read more
VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to clinical trials, enhance the participant experience, and reduce site burden. Learn … Read more
Henrik Watz, MD, PhD, has been named a 2024 Top Scholar by ScholarGPS, ranked #34 globally among chronic obstructive pulmonary disease (COPD) researchers over the past five years, and recognized among the top 0.5% of all researchers worldwide. Over the past year, Dr. Watz has: Presented compelling real-world data at ATS 2025 on the long-term … Read more
Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma. Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. Notably, more than half achieved asthma remission within two years of … Read more
When Velocity Clinical Research launched in December 2017, it had just two sites. Owned sites (SMOs) were the prevalent model at the time, and site networks were a collection of independent sites with a single point of contact. Velocity offered an alternative – a wholly owned and fully integrated network of clinical trial sites. That … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t still have some clout (the UK ranks fourth globally for Phase … Read more